- Home
- ELAB vs MBIO Comparison
ELAB vs MBIO Comparison
Compare ELAB & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.13
Company Overview
Basic Information| Metric | ELAB | MBIO |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELAB | MBIO |
|---|---|---|
| Price | $5.81 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 501.4K | 90.9K |
| Earning Date | 03-27-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $0.89 |
| 52 Week High | $398.86 | $13.29 |
Technical Indicators
Market Signals| Indicator | ELAB | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 72.16 | 49.66 |
| Support Level | $1.25 | $0.92 |
| Resistance Level | $9.59 | $1.15 |
| Average True Range (ATR) | 0.76 | 0.07 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 55.22 | 86.99 |
Price Performance
Historical Comparison ELAB
MBIO
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.